Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs.

@article{Coiffier1991PrognosticFI,
  title={Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs.},
  author={Bertrand Coiffier and Christian Gisselbrecht and Julie Marie Vose and Herv{\'e} Tilly and Raoul Herbrecht and Andr{\'e} Bosly and James Olen Armitage},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1991},
  volume={9 2},
  pages={211-9}
}
The objectives of this study were to determine prognostic factors for response to treatment, freedom-from-relapse (FFR) survival, and overall survival of 737 aggressive malignant lymphoma patients treated with the doxorubicin, cyclophosphamide, vindesine, bleomycin, methylprednisolone, methotrexate with leucovorin, ifosfamide, etoposide, asparaginase, and cytarabine (LNH-84) regimen; to construct a prognostic index with factors isolated by multivariate analyses; and to validate this prognostic… CONTINUE READING